z-logo
Premium
Neonatal Co‐Infection with Helicobacter Species Markedly Accelerates the Development of Inflammation‐Associated Colonic Neoplasia in IL‐10 −/– Mice
Author(s) -
Hale Laura P.,
Perera Dinushi,
Gottfried Marcia R.,
MaggioPrice Lillian,
Srinivasan Sudha,
Marchuk Douglas
Publication year - 2007
Publication title -
helicobacter
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 79
eISSN - 1523-5378
pISSN - 1083-4389
DOI - 10.1111/j.1523-5378.2007.00552.x
Subject(s) - inflammation , medicine , immunology , inflammatory bowel disease , immune system , colorectal cancer , cancer , gastroenterology , disease
Abstract Background:  Inflammatory bowel disease (IBD) is hypothesized to represent an aberrant immune response against enteric bacteria that occurs in a genetically susceptible host. Humans and mice with IBD are at markedly increased risk for colonic neoplasia. However, the long lead time required before development of inflammation‐associated colon neoplasia in commonly used murine models of IBD slows the development of effective chemopreventative therapies. Materials and methods:  Neonatal coinfection with Helicobacter typhlonius and Helicobacter rodentium was used to trigger the onset of IBD in mice deficient in the immunoregulatory cytokine interleukin (IL)‐10. The severity of colon inflammation and incidence of neoplasia was determined histologically. Results:  IL‐10 −/– mice demonstrated early onset, severe colon inflammation following neonatal infection with H. typhlonius and H. rodentium . The incidence of inflammation‐associated colon neoplasia was ~95% at a mean age of 21 ± 2 weeks. Mutation of endoglin, an accessory receptor for TGF‐β, did not affect the severity of IBD or the incidence of neoplasia in this model. Conclusions:  The rapid onset of severe colon inflammation and multiple neoplastic lesions in the colons of IL‐10 −/– mice neonatally coinfected with H. typhlonius and H. rodentium makes this model well‐suited for investigating the mechanisms involved in inflammation‐associated colon cancer as well as its chemoprevention.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here